CONTACTStaffCAREER OPPORTUNITIESADVERTISE WITH USPRIVACY POLICYPRIVACY PREFERENCESTERMS OF USELEGAL NOTICE
© 2024 Pride Publishing Inc.
All Rights reserved
All Rights reserved
By continuing to use our site, you agree to our Private Policy and Terms of Use.
Drugmakers Bristol-Myers Squibb, Gilead Sciences, and Merck on Sunday announced that the companies have begun work on the development of a once-daily, fixed-dose pill that contains three anti-HIV drugs made by the firms. The single pill would contain a full day's dosing of Gilead's nucleoside reverse transcriptase inhibitor Emtriva, its nucleotide reverse transcriptase inhibitor Viread, and the nonnucleoside reverse transcriptase inhibitor Sustiva, which is marketed in the United States by BMS and in many other countries by Merck. The companies also are considering copackaging options for the three individual medications. Gilead has already filed for Food and Drug Administration approval of a single-tablet combination of Viread and Emtriva. AIDS caregivers say that because HIV patients need to take up to 95% of their antiretroviral medications on time to avoid the development of drug-resistance virus, regimens that are simpler to stick to--such as once-daily pills--are an important tool in HIV treatment. The three-drug pill being discussed would be available in both developed and developing nations, company officials say. "Given the complexities of this disease and the unique challenges in delivering care and treatment in resource-limited settings, we recognize the need to work together and combine our expertise to find innovative solutions," said BMS chairman and CEO Peter R. Dolan. There was no indication by the companies as to when a three-drug pill would be ready for human testing or to when they hope to submit the pill for FDA marketing approval.
Want more breaking equality news & trending entertainment stories?
Check out our NEW 24/7 streaming service: the Advocate Channel!
Download the Advocate Channel App for your mobile phone and your favorite streaming device!
From our Sponsors
Most Popular
Here Are Our 2024 Election Predictions. Will They Come True?
November 07 2023 1:46 PM
Meet all 37 of the queer women in this season's WNBA
April 17 2024 11:24 AM
17 Celebs Who Are Out & Proud of Their Trans & Nonbinary Kids
November 30 2023 10:41 AM
Here Are the 15 Most LGBTQ-Friendly Cities in the U.S.
November 01 2023 5:09 PM
Which State Is the Queerest? These Are the States With the Most LGBTQ+ People
December 11 2023 10:00 AM
These 27 Senate Hearing Room Gay Sex Jokes Are Truly Exquisite
December 17 2023 3:33 PM
10 Cheeky and Homoerotic Photos From Bob Mizer's Nude Films
November 18 2023 10:05 PM
42 Flaming Hot Photos From 2024's Australian Firefighters Calendar
November 10 2023 6:08 PM
These Are the 5 States With the Smallest Percentage of LGBTQ+ People
December 13 2023 9:15 AM
Here are the 15 gayest travel destinations in the world: report
March 26 2024 9:23 AM
Watch Now: The Daily
Trending stories from our video partner Advocate Channel.
For more videos and shows go to advocatechannel.com.
Trending stories from our video partner Advocate Channel.
For more videos and shows go to advocatechannel.com.
Latest Stories
Over 90% of trans youth live in states pushing anti-trans legislation: report
April 23 2024 10:08 PM
George Santos pulls out of New York congressional race
April 23 2024 7:04 PM
Biden will hammer Trump over abortion bans in Florida speech
April 23 2024 5:00 AM
Tristan Snell, who brought down Trump University, sees conviction in hush money case
April 22 2024 7:36 PM
Joe Biden admin marks Earth Day with major environmental initiatives
April 22 2024 4:18 PM
Texas Gov. Greg Abbott: 'We want to end' trans and gender nonconforming teachers
April 22 2024 4:13 PM
Nonbinary 17-year-old killed two years after being reported missing
April 22 2024 3:46 PM